KING OF PRUSSIA, PA — CSL Behring has announced a significant development aimed at improving the treatment experience for patients with Alpha-1 antitrypsin deficiency. The Pennsylvania-based company has introduced 4- and 5-gram vial sizes of its product ZEMAIRA, a major shift from the previously available 1-gram packaging. The change is set to streamline the preparation process for ZEMAIRA, reduce waste, and potentially simplify administration.
ZEMAIRA is an Alpha1-Proteinase Inhibitor (Human) indicated for maintenance treatment in adults with severe Alpha-1 antitrypsin deficiency. The dosage is determined by the patient’s weight, which means a person weighing around 183 pounds would typically require five 1-gram vials. The new, larger vial sizes mean healthcare professionals will need to reconstitute fewer ZEMAIRA vials per dose, saving valuable time and resources.
Shannen Silvestrini, Director of ZEMAIRA Marketing at CSL Behring, said, “We have been providing ZEMAIRA to the Alpha-1 community for 20 years and are committed to listening and addressing unmet needs through our therapies and patient programs.” Silvestrini added that the larger vial sizes will continue to provide a safe and effective treatment option while making it easier for healthcare professionals to prepare ZEMAIRA for their patients.
The introduction of the larger vials also aligns with CSL’s sustainability strategy. By reducing the number of vials needed, the move contributes positively to the company’s efforts to minimize waste in its supply chain and throughout production. This focus on waste reduction forms a key part of the Environmental Pillar of CSL’s Sustainability Strategy.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.